We are live on
!
Find out more
AP
Antipodes Partners Portfolio holdings
AUM
$5.19B
1-Year Est. Return
36.17%
This Fund
S&P 500
This Quarter
Est. Return
+4.52%
1 Year Est. Return
+36.17%
3 Year Est. Return
+104%
5 Year Est. Return
+169.34%
10 Year Est. Return
–
AUM
$5.19B
AUM Growth
+$432M
(+9.1%)
Cap. Flow
+$355M
Cap. Flow
% of AUM
6.83%
Top 10 Holdings %
Top 10 Hldgs %
35.34%
Holding
150
New
22
Increased
48
Reduced
47
Closed
24
Top Buys
| 1 |
NVIDIA
NVDA
|
+$130M |
| 2 |
HTO
H2O America
HTO
|
+$102M |
| 3 |
Walt Disney
DIS
|
+$69.5M |
| 4 |
Workday
WDAY
|
+$69M |
| 5 |
Progressive
PGR
|
+$60.7M |
Top Sells
| 1 |
Advanced Micro Devices
AMD
|
+$62.8M |
| 2 |
Meta Platforms (Facebook)
META
|
+$53.2M |
| 3 |
Lennar Class A
LEN
|
+$34.4M |
| 4 |
Westlake Corp
WLK
|
+$30.8M |
| 5 |
Eldorado Gold
EGO
|
+$25M |
Sector Composition
| 1 | Utilities | 28.74% |
| 2 | Technology | 13.47% |
| 3 | Healthcare | 12.72% |
| 4 | Energy | 9.26% |
| 5 | Consumer Discretionary | 8.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Boston Scientific
BSX
$64.4B
| $70.8K | ﹤0.01% |
+1,128
| New | +$90.2K |
|
102
SI-BONE Inc
SIBN
$765M
| $70.3K | ﹤0.01% |
5,564
+4,094
| +279% | +$64.1K |
|
103
Teva Pharmaceuticals
TEVA
$36.8B
| $67.3K | ﹤0.01% |
2,234
+148
| +7% | +$4.76K |
|
104
Ormat Technologies
ORA
$6.71B
| $60.4K | ﹤0.01% |
+540
| New | +$62.7K |
|
105
Vertex Pharmaceuticals
VRTX
$122B
| $56.7K | ﹤0.01% |
127
| – | – |
|
106
Natera
NTRA
$39.4B
| $56K | ﹤0.01% |
280
-50
| -15% | -$10.8K |
|
107
GE Aerospace
GE
$370B
| $40K | ﹤0.01% |
141
| – | – |
|
108
Tarsus Pharmaceuticals
TARS
$2.43B
| $38.9K | ﹤0.01% |
+555
| New | +$38.8K |
|
109
argenx
ARGX
$53.9B
| $36.5K | ﹤0.01% |
50
-146
| -74% | -$114K |
|
110
DexCom
DXCM
$28.7B
| $34.8K | ﹤0.01% |
554
-304
| -35% | -$21.2K |
|
111
Tango Therapeutics
TNGX
$4.86B
| $33.9K | ﹤0.01% |
1,622
-2,891
| -64% | -$40.2K |
|
112
IDEAYA Biosciences
IDYA
$3.52B
| $30.6K | ﹤0.01% |
917
-233
| -20% | -$7.82K |
|
113
Dianthus Therapeutics
DNTH
$5.48B
| $30.5K | ﹤0.01% |
364
-95
| -21% | -$5.5K |
|
114
Disc Medicine
IRON
$2.87B
| $30.4K | ﹤0.01% |
476
+57
| +14% | +$3.96K |
|
115
Nuvalent
NUVL
$9.81B
| $28.2K | ﹤0.01% |
275
-116
| -30% | -$11.8K |
|
116
908 Devices
MASS
$329M
| $26.9K | ﹤0.01% |
4,402
-692
| -14% | -$4.33K |
|
117
AtaiBeckley Inc
ATAI
$1.95B
| $26.7K | ﹤0.01% |
7,529
+448
| +6% | +$1.69K |
|
|
TERN
118
DELISTED
Terns Pharmaceuticals
TERN
| $24K | ﹤0.01% |
+455
| New | +$18.7K |
|
119
Relmada Therapeutics
RLMD
$641M
| $21.1K | ﹤0.01% |
+3,035
| New | +$14.4K |
|
120
Viridian Therapeutics
VRDN
$2.09B
| $16.3K | ﹤0.01% |
834
-316
| -27% | -$9.38K |
|
121
Oric Pharmaceuticals
ORIC
$1.1B
| $16.2K | ﹤0.01% |
1,278
-1,121
| -47% | -$12.7K |
|
|
BIOA
122
BioAge Labs
BIOA
$1.01B
| $16K | ﹤0.01% |
+915
| New | +$17.6K |
|
123
Cabaletta Bio
CABA
$437M
| $15.1K | ﹤0.01% |
5,616
-11,571
| -67% | -$32.1K |
|
124
Sociedad Química y Minera de Chile
SQM
$20.1B
| $14.7K | ﹤0.01% |
182
| – | – |
|
|
ANL
125
Adlai Nortye
ANL
$621M
| $14.2K | ﹤0.01% |
+2,051
| New | +$13.7K |
|
Similar funds
AUB
KACA
DDC
MIM
AAI
SCM
SDIC
SC